Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

NCT01323517 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab, Melphalan and Dactinomycin

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]